Mayne Pharma Launches US Pharmacy Platform to Cut Middlemen and Capture Margins
Mayne Pharma is an ASX-listed specialty pharmaceutical company with a 40-year track record of innovation in developing and commercializing pharmaceuticals. The company focuses on improving patient access to life-enhancing medications through a robust portfolio of branded and generic drugs, with key therapeutic areas including women’s health and dermatology. Their expertise lies in developing novel oral drug delivery systems and creating innovative pharmaceutical technologies that have been successfully marketed worldwide.
In addition to their pharmaceutical product line, Mayne Pharma operates a full-service contract development and manufacturing organization (CDMO) that provides comprehensive pharmaceutical development, analytical testing, and commercial manufacturing services to clients globally. Their mission is to partner with clients from “concept to commercialization,” helping to develop pharmaceutical products that can positively impact patients’ lives across different markets.
The company is committed to sustainability and corporate responsibility, recognizing its role in the global community. They prioritize ensuring the safety and well-being of their employees, supporting local communities, and maintaining environmental stewardship. With a strategic approach to business and a focus on innovation, Mayne Pharma continues to strengthen its market presence and work towards delivering high-quality, accessible medications that can improve patient outcomes.
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.